Who
Asaf Danziger
Director
Company insider
Files Form 4 as: Chief Executive Officer, NovoCure.
In numbers
- Trades disclosed
- 199
- Buys
- 2
- Sells
- 55
- Bought
- $660K
- Sold
- $201.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Oct 2015
- Last trade
- 30 Jun 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 1 Jul 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | $2,988268 at $11.15 | filing |
| 30 Jun 2026filed 1 Jul 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | $2,988268 at $11.15 | filing |
| 31 Dec 2025filed 8 Jan 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | $111 at $10.99 | filing |
| 30 Jun 2025filed 1 Jul 2025 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | $13K833 at $15.13 | filing |
| 1 Jan 2025filed 3 Jan 2025 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 31 Dec 2024filed 3 Jan 2025 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | $6,077412 at $14.75 | filing |
| 28 Jun 2024filed 6 Aug 2024 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | $15K1,239 at $12.24 | filing |
| 30 Jun 2023filed 6 Jul 2023 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | $13K367 at $35.28 | filing |
| 6 Jan 2023filed 9 Jan 2023 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | $2,43039 at $62.31 | filing |
| 5 Jan 2023filed 9 Jan 2023 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 5 Jan 2023filed 9 Jan 2023 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code M | —187,500 at $0.00 | filing |
| 5 Jan 2023filed 9 Jan 2023 | NVCR NovoCureMedical Devices | SEC FORM 4 Code M | $287K25,000 at $11.46 | filing |
| 5 Jan 2023filed 9 Jan 2023 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $931K8,369 at $111.23 | filing |
| 5 Jan 2023filed 9 Jan 2023 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $226K2,000 at $112.86 | filing |
| 5 Jan 2023filed 9 Jan 2023 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $522K4,568 at $114.35 | filing |
| 5 Jan 2023filed 9 Jan 2023 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $427K3,702 at $115.21 | filing |
| 5 Jan 2023filed 9 Jan 2023 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $162K1,395 at $116.06 | filing |
| 5 Jan 2023filed 9 Jan 2023 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $117K999 at $117.01 | filing |
| 5 Jan 2023filed 9 Jan 2023 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $252K2,123 at $118.47 | filing |
| 5 Jan 2023filed 9 Jan 2023 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $160K1,344 at $119.35 | filing |
News
Reviewing NeurAxis (NASDAQ:NRXS) & NovoCure (NASDAQ:NVCR)NVCR · tickerreport.com · 15 Oct 2026NovoCure (NASDAQ:NVCR) and Medline (NASDAQ:MDLN) Financial AnalysisNVCR · themarketsdaily.com · 8 Oct 2026NovoCure (NASDAQ:NVCR) versus Kewaunee Scientific (NASDAQ:KEQU) Head-To-Head ReviewNVCR · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name Asaf Danziger; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.